These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 27378383)

  • 1. Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients.
    Bracht T; Mölleken C; Ahrens M; Poschmann G; Schlosser A; Eisenacher M; Stühler K; Meyer HE; Schmiegel WH; Holmskov U; Sorensen GL; Sitek B
    J Transl Med; 2016 Jul; 14(1):201. PubMed ID: 27378383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients.
    Mölleken C; Ahrens M; Schlosser A; Dietz J; Eisenacher M; Meyer HE; Schmiegel W; Holmskov U; Sarrazin C; Sorensen GL; Sitek B; Bracht T
    Clin Mol Hepatol; 2019 Mar; 25(1):42-51. PubMed ID: 30449076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MFAP4: a candidate biomarker for hepatic and pulmonary fibrosis?
    Mölleken C; Poschmann G; Bonella F; Costabel U; Sitek B; Stühler K; Meyer HE; Schmiegel WH; Marcussen N; Helmer M; Nielsen O; Hansen S; Schlosser A; Holmskov U; Sorensen GL
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Mar; 33(1):41-50. PubMed ID: 27055835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of liver fibrosis severity in alcoholic liver disease by human microfibrillar-associated protein 4.
    Madsen BS; Thiele M; Detlefsen S; Sørensen MD; Kjaergaard M; Møller LS; Rasmussen DN; Schlosser A; Holmskov U; Trebicka J; Sorensen GL; Krag A;
    Liver Int; 2020 Jul; 40(7):1701-1712. PubMed ID: 32339377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of disease-associated protein expression using quantitative proteomics—fibulin-5 is expressed in association with hepatic fibrosis.
    Bracht T; Schweinsberg V; Trippler M; Kohl M; Ahrens M; Padden J; Naboulsi W; Barkovits K; Megger DA; Eisenacher M; Borchers CH; Schlaak JF; Hoffmann AC; Weber F; Baba HA; Meyer HE; Sitek B
    J Proteome Res; 2015 May; 14(5):2278-86. PubMed ID: 25807371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microfibrillar-associated protein 4 in health and disease.
    Kanaan R; Medlej-Hashim M; Jounblat R; Pilecki B; Sorensen GL
    Matrix Biol; 2022 Aug; 111():1-25. PubMed ID: 35644509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum N-glycan markers for diagnosing liver fibrosis induced by hepatitis B virus.
    Cao X; Shang QH; Chi XL; Zhang W; Xiao HM; Sun MM; Chen G; An Y; Lv CL; Wang L; Nan YM; Chen CY; Tan ZN; Liu XE; Zhuang H
    World J Gastroenterol; 2020 Mar; 26(10):1067-1079. PubMed ID: 32205997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection.
    El-Kamary SS; Mohamed MM; El-Raziky M; Shardell MD; Shaker OG; ElAkel WA; Esmat G
    Liver Int; 2013 Aug; 33(7):982-90. PubMed ID: 23509874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A panel of a mitogenic (PDGF), biochemical (albumin) and demographic (age) parameters for the non-invasive assessment of hepatic fibrosis.
    Attallah AM; Albannan MS; Omran MM; Zayed R; Saif S; Farid A; Hassany M; Yosry A; Omran D
    Br J Biomed Sci; 2019 Jul; 76(3):105-110. PubMed ID: 30924403
    [No Abstract]   [Full Text] [Related]  

  • 10. Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B.
    Marcellin P; Martinot-Peignoux M; Asselah T; Batrla R; Messinger D; Rothe V; Lau G; Liaw YF
    Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1532-9.e1. PubMed ID: 25542306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of novel biomarkers of liver cirrhosis by proteomic analysis.
    Mölleken C; Sitek B; Henkel C; Poschmann G; Sipos B; Wiese S; Warscheid B; Broelsch C; Reiser M; Friedman SL; Tornøe I; Schlosser A; Klöppel G; Schmiegel W; Meyer HE; Holmskov U; Stühler K
    Hepatology; 2009 Apr; 49(4):1257-66. PubMed ID: 19177598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum MFAP4, a novel potential biomarker for liver cirrhosis screening, correlates with transient elastography in NAFLD patients.
    Kanaan R; Yaghi C; Saade Riachy C; Schlosser A; Hamade A; Holmskov U; Medlej-Hashim M; Sørensen GL; Jounblat R
    JGH Open; 2023 Mar; 7(3):197-203. PubMed ID: 36968563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microfibrillar-Associated Protein 4: A Potential Biomarker for Screening for Liver Fibrosis in a Mixed Patient Cohort.
    Sækmose SG; Mössner B; Christensen PB; Lindvig K; Schlosser A; Holst R; Barington T; Holmskov U; Sorensen GL
    PLoS One; 2015; 10(10):e0140418. PubMed ID: 26460565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients.
    Liu XD; Wu JL; Liang J; Zhang T; Sheng QS
    World J Gastroenterol; 2012 Jun; 18(22):2784-92. PubMed ID: 22719186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals.
    Saleh SA; Salama MM; Alhusseini MM; Mohamed GA
    World J Gastroenterol; 2020 Jun; 26(21):2864-2876. PubMed ID: 32550761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease.
    Pavlov CS; Casazza G; Nikolova D; Tsochatzis E; Burroughs AK; Ivashkin VT; Gluud C
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010542. PubMed ID: 25612182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS.
    Karatayli SC; Alagöz SG; Mizrak D; Sayki M; Ozkan M; Savaş B; Erden E; Cinar K; Idılman R; Yurdaydin C; Bozdayi AM
    Turk J Gastroenterol; 2012 Feb; 23(1):46-53. PubMed ID: 22505379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Localization of microfibrillar-associated protein 4 (MFAP4) in human tissues: clinical evaluation of serum MFAP4 and its association with various cardiovascular conditions.
    Wulf-Johansson H; Lock Johansson S; Schlosser A; Trommelholt Holm A; Rasmussen LM; Mickley H; Diederichsen AC; Munkholm H; Poulsen TS; Tornøe I; Nielsen V; Marcussen N; Vestbo J; Sækmose SG; Holmskov U; Sorensen GL
    PLoS One; 2013; 8(12):e82243. PubMed ID: 24349233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steatosis affects the performance of liver stiffness measurement for fibrosis assessment in patients with genotype 1 chronic hepatitis C.
    Macaluso FS; Maida M; Cammà C; Cabibbo G; Cabibi D; Alduino R; Di Marco V; Craxì A; Petta S
    J Hepatol; 2014 Sep; 61(3):523-9. PubMed ID: 24815874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver Fibrosis Evaluation Using Real-time Shear Wave Elastography in Hepatitis C-Monoinfected and Human Immunodeficiency Virus/Hepatitis C-Coinfected Patients.
    Verlinden W; Bourgeois S; Gigase P; Thienpont C; Vonghia L; Vanwolleghem T; Michielsen P; Francque S
    J Ultrasound Med; 2016 Jun; 35(6):1299-308. PubMed ID: 27151906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.